A dose-response study of vitamin D3 supplementation in healthy Chinese: a 5-arm randomized, placebo-controlled trial.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
vitamin D3 supplementation | increase | serum 25-hydroxyvitamin D [25(OH)D] | Chinese adults | 6.0 (6.5), 21.7 (15.8), 26.3 (12.6), 32.0 (12.8) and 36.3 (26.0) nmol/L for 0, 400, 800, 1200 and 2000 IU/d | increased | #1 |
vitamin D3 supplementation | decrease | vitamin D deficiency | Chinese adults | approximately 19, 53, 67, 77 and 80 % | reversion of vitamin D deficiency | #2 |
800 IU vitamin D3 daily intake | increase | 25(OH)D | Chinese | at least 97.5 % | reached a targeted 25(OH)D ≥ 30 nmol/L | #3 |
2000 IU/d vitamin D3 | no change | 25(OH)D | Chinese | - | not reached a targeted 25(OH)D ≥ 50 nmol/L | #4 |
vitamin D3 supplementation | decrease | PTH concentration | - | r = -0.39 | inversely associated with | #5 |
vitamin D3 supplementation | no change | serum calcium | - | - | No between-group differences were observed | #6 |
vitamin D3 supplementation | no change | alanine transaminase | - | - | No between-group differences were observed | #7 |
vitamin D3 supplementation | no change | aspartate aminotransferase | - | - | No between-group differences were observed | #8 |
vitamin D3 supplementation | no change | gamma-glutamyltransferase | - | - | No between-group differences were observed | #9 |
vitamin D3 supplementation | no change | creatinine | - | - | No between-group differences were observed | #10 |
Supplementation with 400, 800, 1200 or 2000 IU/d vitamin D | decrease | vitamin D deficiency | - | with various degrees | could improve | #11 |
PURPOSE: To determine the dose-response of vitamin D3 supplementation on serum 25-hydroxyvitamin D [25(OH)D] among Chinese adults. METHODS: In this 5-arm, randomized, double-blinded controlled trial, 76 healthy participants were assigned to orally administrate 0, 400, 800, 1200 or 2000 IU/d of vitamin D3 for 16 weeks. Serum 25(OH)D, parathyroid hormone, calcium, biomarkers of liver and renal function were measured at multiple time points. RESULTS: The mean (SD) serum 25(OH)D at baseline was 31.6 (8.7) nmol/L, and the dose-response relationship was curvilinear with a plateau around 6 weeks for all doses. At week 16, 25(OH)D was increased by 6.0 (6.5), 21.7 (15.8), 26.3 (12.6), 32.0 (12.8) and 36.3 (26.0) nmol/L for 0, 400, 800, 1200 and 2000 IU/d (all P ≤ 0.002), corresponding to approximately 19, 53, 67, 77 and 80 % of reversion of vitamin D deficiency, respectively. Daily intake of 800 IU vitamin D3 reached a targeted 25(OH)D ≥ 30 nmol/L in at least 97.5 % of Chinese, but not a targeted 25(OH)D ≥ 50 nmol/L even with 2000 IU/d. Change of 25(OH)D was inversely associated with change of PTH concentration (r = -0.39, P < 0.001) after controlling for age and sex. No between-group differences were observed in terms of the change in serum calcium, alanine transaminase, aspartate aminotransferase, gamma-glutamyltransferase and creatinine (P ≥ 0.22). CONCLUSIONS: Supplementation with 400, 800, 1200 or 2000 IU/d vitamin D could improve the vitamin D deficiency with various degrees. Whether 2000 IU/d vitamin D3 would generate a better result without side effect requires more studies with larger samples in future.